Free tool
FAERS Monitor: Lovenox
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022138 or its brand name (Lovenox, Enoxaparin Sodium). Reports on generic versions are filed under their own applications.
Reports
58,051
Serious
50,417
87% of reports
Hospitalization
31,135
Death reported
8,973
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use2,665
- dyspnoea2,456
- nausea2,434
- diarrhoea2,330
- anaemia2,259
- thrombocytopenia2,131
- pyrexia2,098
- fatigue2,034
- vomiting1,905
- pulmonary embolism1,831
- death1,772
- pneumonia1,716
- asthenia1,650
- acute kidney injury1,621
- fall1,573
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,257 |
| 2005 | 1,329 |
| 2006 | 1,244 |
| 2007 | 1,240 |
| 2008 | 1,501 |
| 2009 | 1,763 |
| 2010 | 1,941 |
| 2011 | 2,327 |
| 2012 | 2,297 |
| 2013 | 1,935 |
| 2014 | 2,315 |
| 2015 | 2,754 |
| 2016 | 2,904 |
| 2017 | 2,745 |
| 2018 | 3,649 |
| 2019 | 3,436 |
| 2020 | 3,596 |
| 2021 | 3,368 |
| 2022 | 3,956 |
| 2023 | 3,666 |
| 2024 | 3,309 |
| 2025 | 3,268 |
| 2026 | 2,249 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,996,108 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pulmonary embolismSignal | 1,831 | 7.1 | 6.8 | 9,445 |
| thrombocytopeniaSignal | 2,131 | 7.0 | 6.7 | 10,842 |
| anaemiaSignal | 2,259 | 4.3 | 4.2 | 5,768 |
| acute kidney injurySignal | 1,621 | 3.9 | 3.7 | 3,433 |
| pyrexiaSignal | 2,098 | 2.2 | 2.1 | 1,393 |
| pneumonia | 1,716 | 1.9 | 1.8 | 770 |
| fall | 1,573 | 1.7 | 1.6 | 474 |
| asthenia | 1,650 | 1.6 | 1.5 | 368 |
| dyspnoea | 2,456 | 1.6 | 1.5 | 526 |
| vomiting | 1,905 | 1.5 | 1.4 | 291 |
| diarrhoea | 2,330 | 1.3 | 1.3 | 174 |
| nausea | 2,434 | 1.1 | 1.1 | 30 |
| off label use | 2,665 | 1.1 | 1.1 | 27 |
| fatigue | 2,034 | 0.9 | 0.9 | 6 |
| death | 1,772 | 0.7 | 0.7 | 161 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.